Previous studies have confirmed that mRNA and protein levels of HLA-DMB are highly expressed in tumor samples from patients with advanced serous ovarian cancer with a large number of tumor-penetrating CD8 T lymphocytes, which can significantly prolong the median survival time [35]. Here, HLA-DMB is linked to ovarian serous adenocarcinoma.